Characteristics and Risk Factors of Immune-Related Adverse Events in Cancer Patients

113 cancer patients experienced immune-related adverse events in a cohort of 297 patients receiving immune checkpoint inhibitor combination therapy. Yao Qiu published this clinical study on figshare in 2026, analyzing incidence, severity, onset time, and risk factors for adverse events. The findings suggest corticosteroid use is a protective factor and combination with targeted therapy increases risk for endocrine adverse events.

Use Cases

• Predicting risk of immune-related adverse events based on patient age and corticosteroid use.
• Analyzing onset time patterns for different adverse event types, such as endocrine toxicities.
• Modeling risk factors for endocrine adverse events based on treatment type and baseline TSH levels.
• Evaluating the impact of different combination therapies (chemotherapy, targeted therapy) on adverse event incidence.

Strengths

• Includes data from 297 cancer patients, with 282 receiving combination therapy.
• Analyzes specific risk factors with odds ratios and confidence intervals, such as age≥65 years (OR=0.487).
• Reports onset time metrics, including average time of 2.43 treatment cycles and that 85.25% emerged within 4 cycles.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or source bias inherent to the single study on figshare.

Provenance

Source

figshare

Collection Method

Data collected from 297 cancer patients, including demographic data, treatment regimens, concomitant medications, and laboratory biomarkers.

Freshness

Last updated 2026-05-29 04:46:52; freshness should be verified.